BioSpace News Archive

Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced the appointment of Sebastian Guth, PhD, to the company’s Board of Directors.

PTC Therapeutics, Inc. announced that Waylivra™ has successfully received Category 1 classification from Câmara de Regulação do Mercado de Medicamentos - CMED in Brazil.

NexGel, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), today announced that Adam Levy, Chief Executive Officer of NEXGEL, will participate in the H.C. Wainwright Bioconnect Conference to be held virtually on January 10-13, 2022.

OnQuality Pharmaceuticals (“OnQuality”), today announced that Part 1 of the Phase 2 NOVA-II clinical trial evaluating OQL011 met the company’s expectations of safety, efficacy and the patient reported outcome of Hand-Foot Skin Reaction (HFSR)-related pain.

IVERIC bio, Inc. announced that Pravin U. Dugel, M.D., President, will present an overview of the Company at the H.C. Wainwright BioConnect Virtual Conference, being held virtually from January 10-13, 2022.

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, announced that President and Chief Executive Officer Bill Hinshaw will be presenting at the H.C. Wainwright BioConnect Conference.

Exelixis, Inc. announced the appointment of Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer.

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022.

Amylyx Pharmaceuticals, Inc. today announced it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for AMX0035 (sodium phenylbutyrate (PB) and ursodoxicoltaurine (TURSO; also known as taurursodiol)) for the treatment of amyotrophic lateral sclerosis (ALS).

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference.